The only FDA-approved treatment evaluated in 2 large multicenter studies of patients with Peyronie's disease1*

Randomized, double-blind, placebo-controlled studies that evaluated both erectile curvature and Bother score1,2

  • Studies 1 and 2 were published in The Journal of Urology as IMPRESS I and II (The Investigation for Maximal Peyronie’s Reduction Efficacy and Safety Studies).
  • 551 received XIAFLEX®, 281 received placebo.1
  • All Intent-to-treat (ITT)=randomized men who received at least 1 dose of study drug.3,4
  • Modified intent-to-treat (mITT) population=patients with erectile curvature deformity measurement and Peyronie's Disease Questionnaire (PDQ) assessment at baseline, and at 1 or more subsequent time points, and who had engaged in vaginal intercourse within 3 months prior to each PDQ assessment.1

Study design

The efficacy of XIAFLEX® was evaluated in 2 randomized, double-blind, placebo-controlled, multicenter trials in 832 adult males with Peyronie’s disease (Studies 1 and 2). In these trials, patients were given up to 4 treatment cycles of XIAFLEX® or placebo (Weeks 0, 6, 12, 18), and were followed in a nontreatment follow-up period (Weeks 24–52). In each treatment cycle, 2 injections of XIAFLEX® or 2 injections of placebo were administered 1 to 3 days apart. A penile modeling procedure was performed 1 to 3 days after the second injection. The treatment cycle was repeated at ~6 week intervals for a maximum of 8 total injection procedures and 4 total modeling procedures. Patients also performed at-home daily penile modeling for 6 weeks.1

Before the first dose of study drug was administered, eligible patients were stratified by the degree of curvature deformity (30°–60°, and 61°–90°) and then randomized into 2 treatment groups to receive either XIAFLEX® or placebo in a 2:1 ratio.1

Study entry

  • In Studies 1 and 2, the co-primary endpoints were1:
    • The percentage change from baseline to Week 52 in erectile curvature deformity (erectile curvature)
    • The change from baseline to Week 52 in the Bother domain score of the PDQ
  • Patients must have had erectile curvature deformity of ≥30 degrees in the stable phase of Peyronie’s disease1
  • Patients were excluded if they had a ventral curvature deformity, an isolated hourglass deformity, or a calcified plaque that could have interfered with the injection technique1
    • A total of 156 patients presented with plaques that showed some calcification that did not interfere with the injection of XIAFLEX®, as identified using ultrasound or X-ray5
  • At baseline, penile pain was either not present or was mild in most (98%) patients1
  • At baseline, approximately 50% of patients in the XIAFLEX® clinical trials had a history of erectile dysfunction1

Improvement in erectile curvature after up to 4 cycles of XIAFLEX® from baseline to Week 52 (co-primary endpoint)1

 

A graph of clinical data results for Studies 1 and 2

MEN WHO RECEIVED XIAFLEX® ACHIEVED THE FOLLOWING TREATMENT DIFFERENCE IN ERECTILE CURVATURE COMPARED TO PLACEBO1†

Study 1

17.2%

treatment difference
vs placebo

P<0.01

Study 2

11.4%

treatment difference
vs placebo

P<0.01

95% CI

Mean percentage change, treatment difference, 95% CI, and P value were based on an analysis of variance (ANOVA) model with factors for treatment, stratum of baseline erectile curvature, and their interaction and using last observation carried forward (LOCF) in the mITT population. The mITT population was defined as all randomized subjects who had both an erectile curvature deformity measurement and a PDQ assessment at baseline and at one or more subsequent time points.1

Study 1 Treatment Difference (95% CI): –17.2% (–26.7%, –7.6%).
Study 2 Treatment Difference (95% CI): –11.4% (–19.5%, –3.3%).1

Significant reduction in Patient-Reported Bother (co-primary endpoint)1

  • The reduction in the Bother domain score was numerically similar between patient groups stratified by degree of baseline curvature deformity (30 to 60 degrees, and 61 to 90 degrees).

What is Patient-Reported Bother domain score?

  • Co-primary endpoint in clinical trials was Patient-Reported Bother domain score change from baseline to Week 521
  • The Bother domain score is a composite of the following patient-reported items6-7:
    • Intercourse
    • Erection appearance
    • Erection pain
    • Intercourse frequency

Mean change in Patient-Reported Bother from baseline to Week 52 - Studies 1 and 21

Mean change, treatment difference, 95% CI, and P value all based on an ANOVA model with factors for treatment, stratum of baseline erectile curvature, and their interaction and using LOCF in the mITT population. The mITT population was defined as all randomized patients who had both an erectile curvature deformity measurement and a PDQ assessment at baseline and at one or more subsequent time points.1

P<0.05.

Adverse reactions

Adverse reactions in Study 1 and Study 2 combined occurring in ≥1% of patients treated with XIAFLEX® and
also at a frequency greater than placebo-treated patients after up to 4 treatment cycles1

  • Includes: injection site hematoma and penile hematoma were reported with the verbatim term of penile bruising or injection site bruising in 87% of patients.
  • Includes: injection site swelling, penile edema, penile swelling, local swelling, scrotal swelling, and injection site edema.
  • Includes: injection site pain, penile pain, and injection site discomfort.
  • Includes: contusion, ecchymoses, penile hemorrhage, and injection site hemorrhage.
  • The majority of patients with Peyronie's disease experienced at least 1 adverse reaction (92% XIAFLEX®-treated patients, 61% placebo-treated patients)1
  • Most adverse reactions were local events of the penis and groin and the majority of these events were of mild or moderate severity, and most (79%) resolved within 14 days of the injection1
  • Severe penile hematoma or severe injection site hematoma were reported in 33/551 (6.0%) of patients treated with XIAFLEX® and 0/281 (0%) of placebo-treated patients, in Studies 1 and 2 combined1
  • A popping noise or popping sensation in the penis, sometimes described as "snapping" or "cracking," and sometimes accompanied by detumescence, hematoma, and/or pain, was reported in 73/551 (13.2%) of patients treated with XIAFLEX® and 1/281 (0.3%) of placebo-treated patients1

WHAT ARE PATIENTS SAYING
ABOUT XIAFLEX®?

Hear Their Stories

HOW XIAFLEX® WORKS
 

Learn More

NEED
REIMBURSEMENT SUPPORT?

Learn About Access & Reimbursement

View All
▾

INDICATION

XIAFLEX® is indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.


Important Safety
Information for XIAFLEX

WARNING: CORPORAL RUPTURE (PENILE FRACTURE) OR OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE

Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX‑treated patients in clinical studies. In other XIAFLEX‑treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile "popping" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded. Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 (3.7%) XIAFLEX‑treated patients.

Signs or symptoms that may reflect serious penile injury should be promptly evaluated to assess for corporal rupture or severe penile hematoma which may require surgical intervention.

Because of the risks of corporal rupture or other serious penile injury, XIAFLEX is available for the treatment of Peyronie's disease only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XIAFLEX REMS Program.

INDICATION

XIAFLEX® is indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.


Important Safety
Information for XIAFLEX

WARNING: CORPORAL RUPTURE (PENILE FRACTURE) OR OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE

Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX‑treated patients in clinical studies. In other XIAFLEX‑treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile "popping" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded. Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 (3.7%) XIAFLEX‑treated patients.

Signs or symptoms that may reflect serious penile injury should be promptly evaluated to assess for corporal rupture or severe penile hematoma which may require surgical intervention.

Because of the risks of corporal rupture or other serious penile injury, XIAFLEX is available for the treatment of Peyronie's disease only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XIAFLEX REMS Program.

  • Contraindications: XIAFLEX is contraindicated in the treatment of Peyronie's plaques that involve the penile urethra due to potential risk to this structure and in patients with a history of hypersensitivity to XIAFLEX or to collagenase used in any other therapeutic application or application method
  • Corporal Rupture or Other Serious Injury to the Penis: Injection of XIAFLEX into collagen‑containing structures such as the corpora cavernosa of the penis may result in damage to those structures and possible injury such as corporal rupture (penile fracture). Therefore, XIAFLEX should be injected only into the Peyronie's plaque and care should be taken to avoid injecting into the urethra, nerves, blood vessels, corpora cavernosa or other collagen‑containing structures of the penis. Cases of localized skin and soft tissue necrosis occurring as sequelae of penile hematoma, some requiring surgical intervention, have been reported post-marketing
  • Hypersensitivity Reactions, Including Anaphylaxis: In the double‑blind, placebo‑controlled portions of the clinical trials in Peyronie's disease, a greater proportion of XIAFLEX‑treated patients (4%) compared to placebo‑treated patients (1%) had localized pruritus after up to 4 treatment cycles (involving up to 8 XIAFLEX injection procedures). The incidence of XIAFLEX‑associated pruritus was similar after each injection regardless of the number of injections administered
  • Because XIAFLEX contains foreign proteins, severe allergic reactions to XIAFLEX can occur. Anaphylaxis was reported in a post‑marketing clinical trial in one patient who had previous exposure to XIAFLEX for the treatment of Dupuytren's contracture. Healthcare providers should be prepared to address severe allergic reactions following XIAFLEX injections. The safety of more than one treatment course of XIAFLEX is not known
  • Risk of Bleeding in Patients with Abnormal Coagulation: In the XIAFLEX controlled trials in Peyronie’s disease, 65.5% of XIAFLEX‑treated patients developed penile hematoma, and 14.5% developed penile ecchymosis. Patients with abnormal coagulation (except for patients taking low‑dose aspirin, eg, up to 150 mg per day) were excluded from participating in these studies. Therefore, the efficacy and safety of XIAFLEX in patients receiving anticoagulant medications (other than low‑dose aspirin, eg, up to 150 mg per day) within 7 days prior to XIAFLEX administration is not known. In addition, it is recommended to avoid use of XIAFLEX in patients with coagulation disorders, including patients receiving concomitant anticoagulants (except for low‑dose aspirin)
  • Acute Post-Injection Back Pain Reactions: Post-marketing reports of acute lower back pain reactions, sometimes accompanied by radiation to the lower extremities, chest and arms, muscle spasms, chest pain, paresthesias, headache, and dyspnea, have been received by patients treated with XIAFLEX for Peyronie's disease. These events can be mild to severe in intensity. The events typically lasted for 15 minutes and typically did not require intervention. Administer the smallest number of treatment cycles necessary to treat the patient's curvature deformity
  • Syncope and Presyncope: Most, but not all cases of syncope and presyncope in patients with Peyronie’s disease, occurred in association with post-injection penile pain and hematoma, penile pain with spontaneous erections, and pain during micturition. These potential triggers suggest a vasovagal mechanism. Make patients aware of the potential symptoms that could trigger syncope and presyncope after treatment with XIAFLEX.
    If presyncopal symptoms occur, patients should remain recumbent until symptoms resolve. Syncope may be associated with bodily injuries, including concussion, head abrasion, and other accidental injuries

Adverse Reactions

Clinical trials

  • In the XIAFLEX clinical trials for Peyronie's disease, the most frequently reported adverse drug reactions (≥25%) and at an incidence greater than placebo included: penile hematoma, penile swelling, and penile pain.

Post-marketing experience

  • Acute post-injection lower back pain reactions have occurred in close temporal proximity to XIAFLEX treatments
  • Cases of localized skin and soft tissue necrosis events as sequelae of penile hematoma, some of which required surgical intervention
  • Syncope and presyncope have been reported in men treated with XIAFLEX for Peyronie’s disease. Most, but not all cases occurred in the immediate treatment period or within 1-2 days following injection. Bodily injuries associated with the syncopal events have been reported

Click for full Prescribing Information, including BOXED WARNING and Medication Guide.

References:

1.  XIAFLEX® [package insert]. Malvern, PA: Endo Pharmaceuticals Inc.
2.  Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie's disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199-207.
3.  Data on file. DOF-XPD-03. Endo Pharmaceuticals Inc; January 7, 2016.
4.  Data on file. DOF-XPD-04. Endo Pharmaceuticals Inc; January 7, 2016.
5.  Data on file. DOF-XDC-14. Endo Pharmaceuticals Inc; January 23, 2017.
6.  Data on file. DOF-XPD-02. Endo Pharmaceuticals Inc; September 21, 2015.
7.  Hellstrom WJ, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie’s disease: validation of the Peyronie’s disease questionnaire. J Urol. 2013;190(2):627-634.